Defendant Name: Allarity Therapeutics, Inc.

Defendant Type: Public Company
SIC Code: 9999
CUSIP: 01674450

Initial Case Details

Legal Case Name In the Matter of Allarity Therapeutics, Inc.
First Document Date 12-Mar-2025
Initial Filing Format Administrative Action
File Number 3-22462
Allegation Type Issuer Reporting and Disclosure

Violations Alleged

Exchange Act
• Sec 13(a)
• Rule 13a-11
Securities Act
• Sec 17(a)(2)
• Sec 17(a)(3)

Resolutions

First Resolution Date 12-Mar-2025
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

33-11367 12-Mar-2025 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On March 12, 2025, the SEC instituted settled cease-and-desist proceedings against Allarity Therapeutics, Inc., stating: "This matter involves disclosure failures by Boston-based biopharmaceutical company, Allarity Therapeutics, Inc. (“Allarity” or the “Company”). Between February 2020 and February 2022, through the conduct of certain former officers, these disclosure failures concealed from the public a harsh critique levied by the Food and Drug Administration (“FDA”) about the approval prospects for Allarity’s flagship cancer drug candidate, dovitinib."
33-11367-s 12-Mar-2025 Administrative Summary
Biopharmaceutical Company Settles Charges for Disclosure Failures
On March 12, 2025, the SEC "today announced settled charges against Massachusetts-based biopharmaceutical company Allarity Therapeutics, Inc. for disclosure failures through the conduct of certain former officers that concealed from the public a harsh critique levied by the Food and Drug Administration(FDA) in February 2020 about the likelihood that dovitinib, Allarity's flagship cancer drug candidate, would be approved by the FDA. Allarity has agreed to pay $2.5 million to settle the charges."

Related Actions:

SEC v. Stefano R. Carchedi, Marie L. Foegh Ramwel, and James G. Cullem
Stefano R. Carchedi
Marie L. Foegh Ramwel
James G. Cullem